

2014 TCTAP

Wrap-Up Interview

Fractional Flow Reserve

Moderator

John McB. Hodgson

Interviewees

Eric Van Belle, William F. Fearon, Seung-Jung Park

Issues in Brief

Fractional Flow Reserve

- Guidelines
- Clinical Studies
- FAME 3: FFR Guided PCI vs. CABG

Guidelines

2011 ACCF/AHA/SCAI (Class IIa)

FFR is reasonable to assess angiographic intermediate coronary lesions (50% to 70% diameter stenosis) and can be useful for guiding revascularization decisions in patients with SIHD.

(Evidence: A)

2010 ESC (Class I)


FFR-guided PCI is recommended for detection of ischemia-related lesions when objective evidence of vessel-related ischemia is not available.

FAME: 2 yr Follow Up

- A total of 1,005 patients with multivessel CAD were randomly assigned.


	Angio-Guided N=496	FFR-Guided N=509	p value
Total no. of MACE	139	105	
Individual Endpoints			
Death	19 (3.8)	13 (2.6)	0.25
MI	48 (9.7)	31 (6.1)	0.03
CABG or repeat PCI	61 (12.3)	53 (10.4)	0.35
Composite Endpoints			
Death or MI	63 (12.7)	43 (8.4)	0.03
Death, MI, CABG, or re-PCI	110 (22.2)	90 (17.7)	0.07
Total no. of MACE	139	105	

FFR Penetration Rate in Clinical Practice



Impact of Routine FFR measurement In PCI cohort

Primary Endpoint (Death/MI/Repeat Revascularization)




No. at Risk

Before Routine Use	2178	2066	2011	1960
After Routine Use	2178	2092	2067	2037

Impact of Routine FFR measurement In LM or 3VD cohort


Primary Endpoint (Death/MI/Repeat Revascularization)

Before Routine FFR (2008-2009)



CABG	770	751	743	734
PCI	663	655	634	612
DEFER	34	34	34	34

After Routine FFR (2010-2011)



CABG	494	482	477	471
PCI	566	553	545	531
DEFER	85	85	85	84

Unadjusted K-M curve

FAAME 3

All Comers with 3 vessel CAD
(not involving Left Main)



Amenable to either PCI or CABG per Heart Team

1:1 randomization



FFR-Guided PCI with DES
Stent all lesions with $\text{FFR} \leq 0.80$
(n=775)

Perform **CABG** based on
coronary angiogram
(n=775)

Co-Primary Endpoints

- One Year follow-up for MACCE
- Three Year follow-up for Death, MI, CVA

Discussion

- **Current Status of FFR**
- **Major Barriers to FFR Penetration**
- **FAME 3: FFR Guided PCI vs. CABG**
- **New Hyperemic Stimulants**
- **Future Perspectives on Functional Evaluation**